Dr Amrik Mahal BEM is the Chief Operating Officer for Life Sciences at Amino Data and a senior leader at the intersection of life sciences, technology and pharmaceutical R&D.
Previously, he was AstraZeneca’s Global Head of Information Technology for Research and Head of IT for Sweden, shaping technology strategy and leading the delivery of projects, services and capabilities for R&D.
He was awarded the British Empire Medal (BEM) in the King’s Honours List for services to the UK’s COVID-19 response and to science.
Drawing on experience across Glaxo Wellcome, Oxford Asymmetry, Evotec and academia, he builds diverse, high-performing teams, delivers strategic initiatives and scales innovation to address unmet patient needs.
Amrik is a respected international speaker and chaired the PRISME Board, the pharmaceutical industry’s R&D IT leadership group. He also served on the board of the Pistoia Alliance, supporting collaboration and innovation across the biopharmaceutical ecosystem.
Abstract: The promise of AI to revolutionize drug discovery and development is undeniable. However, moving from isolated AI projects to enterprise-wide, value-driving capabilities presents a formidable challenge for even the most innovative Pharma organizations. The true test lies not in the algorithm, but in the ability to scale.
This panel brings together senior industry leaders to share their strategic perspectives on this critical journey. We will move beyond the hype to address the core operational, technical, and cultural questions that define AI readiness. Our discussion will explore actionable strategies for: